|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MTOR |
Gene summary for MTOR |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MTOR | Gene ID | 2475 |
| Gene name | mechanistic target of rapamycin kinase | |
| Gene Alias | FRAP | |
| Cytomap | 1p36.22 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P42345 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2475 | MTOR | LZE4T | Human | Esophagus | ESCC | 5.59e-03 | 1.11e-01 | 0.0811 |
| 2475 | MTOR | LZE7T | Human | Esophagus | ESCC | 1.14e-07 | 3.37e-01 | 0.0667 |
| 2475 | MTOR | LZE22T | Human | Esophagus | ESCC | 5.81e-05 | 2.77e-01 | 0.068 |
| 2475 | MTOR | LZE24T | Human | Esophagus | ESCC | 2.01e-06 | 1.95e-01 | 0.0596 |
| 2475 | MTOR | P1T-E | Human | Esophagus | ESCC | 9.72e-03 | 1.92e-01 | 0.0875 |
| 2475 | MTOR | P2T-E | Human | Esophagus | ESCC | 8.23e-15 | 2.40e-01 | 0.1177 |
| 2475 | MTOR | P4T-E | Human | Esophagus | ESCC | 1.45e-03 | 1.53e-01 | 0.1323 |
| 2475 | MTOR | P5T-E | Human | Esophagus | ESCC | 1.05e-05 | 1.06e-01 | 0.1327 |
| 2475 | MTOR | P8T-E | Human | Esophagus | ESCC | 5.70e-08 | 1.83e-01 | 0.0889 |
| 2475 | MTOR | P9T-E | Human | Esophagus | ESCC | 1.17e-07 | 1.58e-01 | 0.1131 |
| 2475 | MTOR | P10T-E | Human | Esophagus | ESCC | 1.02e-11 | 3.18e-01 | 0.116 |
| 2475 | MTOR | P11T-E | Human | Esophagus | ESCC | 1.64e-03 | 2.21e-01 | 0.1426 |
| 2475 | MTOR | P12T-E | Human | Esophagus | ESCC | 2.79e-05 | 1.63e-01 | 0.1122 |
| 2475 | MTOR | P15T-E | Human | Esophagus | ESCC | 1.78e-16 | 3.60e-01 | 0.1149 |
| 2475 | MTOR | P16T-E | Human | Esophagus | ESCC | 5.11e-04 | 1.50e-01 | 0.1153 |
| 2475 | MTOR | P17T-E | Human | Esophagus | ESCC | 3.33e-07 | 3.42e-01 | 0.1278 |
| 2475 | MTOR | P19T-E | Human | Esophagus | ESCC | 4.16e-05 | 3.45e-01 | 0.1662 |
| 2475 | MTOR | P20T-E | Human | Esophagus | ESCC | 4.86e-10 | 2.31e-01 | 0.1124 |
| 2475 | MTOR | P21T-E | Human | Esophagus | ESCC | 1.81e-22 | 4.41e-01 | 0.1617 |
| 2475 | MTOR | P22T-E | Human | Esophagus | ESCC | 2.19e-12 | 1.39e-01 | 0.1236 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00345041 | Colorectum | SER | protein localization to nucleus | 74/2897 | 290/18723 | 5.74e-06 | 2.05e-04 | 74 |
| GO:00432811 | Colorectum | SER | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 57/2897 | 209/18723 | 8.08e-06 | 2.74e-04 | 57 |
| GO:00161971 | Colorectum | SER | endosomal transport | 61/2897 | 230/18723 | 1.03e-05 | 3.35e-04 | 61 |
| GO:20001161 | Colorectum | SER | regulation of cysteine-type endopeptidase activity | 62/2897 | 235/18723 | 1.05e-05 | 3.39e-04 | 62 |
| GO:00016671 | Colorectum | SER | ameboidal-type cell migration | 105/2897 | 475/18723 | 6.97e-05 | 1.59e-03 | 105 |
| GO:00510991 | Colorectum | SER | positive regulation of binding | 46/2897 | 173/18723 | 1.12e-04 | 2.34e-03 | 46 |
| GO:00190791 | Colorectum | SER | viral genome replication | 37/2897 | 131/18723 | 1.36e-04 | 2.72e-03 | 37 |
| GO:00160501 | Colorectum | SER | vesicle organization | 69/2897 | 300/18723 | 3.59e-04 | 5.61e-03 | 69 |
| GO:00511011 | Colorectum | SER | regulation of DNA binding | 33/2897 | 118/18723 | 3.70e-04 | 5.71e-03 | 33 |
| GO:00015581 | Colorectum | SER | regulation of cell growth | 90/2897 | 414/18723 | 4.00e-04 | 6.02e-03 | 90 |
| GO:00433881 | Colorectum | SER | positive regulation of DNA binding | 19/2897 | 56/18723 | 4.92e-04 | 7.02e-03 | 19 |
| GO:00431541 | Colorectum | SER | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 24/2897 | 78/18723 | 5.04e-04 | 7.16e-03 | 24 |
| GO:01501161 | Colorectum | SER | regulation of cell-substrate junction organization | 22/2897 | 71/18723 | 7.64e-04 | 9.79e-03 | 22 |
| GO:0051346 | Colorectum | SER | negative regulation of hydrolase activity | 82/2897 | 379/18723 | 8.19e-04 | 1.01e-02 | 82 |
| GO:20001171 | Colorectum | SER | negative regulation of cysteine-type endopeptidase activity | 25/2897 | 86/18723 | 9.88e-04 | 1.17e-02 | 25 |
| GO:00160491 | Colorectum | SER | cell growth | 100/2897 | 482/18723 | 1.07e-03 | 1.24e-02 | 100 |
| GO:00070321 | Colorectum | SER | endosome organization | 24/2897 | 82/18723 | 1.11e-03 | 1.28e-02 | 24 |
| GO:0010466 | Colorectum | SER | negative regulation of peptidase activity | 57/2897 | 262/18723 | 4.15e-03 | 3.38e-02 | 57 |
| GO:00726651 | Colorectum | SER | protein localization to vacuole | 19/2897 | 67/18723 | 5.14e-03 | 3.93e-02 | 19 |
| GO:00510911 | Colorectum | SER | positive regulation of DNA-binding transcription factor activity | 56/2897 | 260/18723 | 5.55e-03 | 4.09e-02 | 56 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05014210 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
| hsa05016210 | Esophagus | ESCC | Huntington disease | 226/4205 | 306/8465 | 1.38e-18 | 8.72e-17 | 4.46e-17 | 226 |
| hsa05022210 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
| hsa05010210 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
| hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa0421829 | Esophagus | ESCC | Cellular senescence | 119/4205 | 156/8465 | 5.89e-12 | 9.40e-11 | 4.81e-11 | 119 |
| hsa05415211 | Esophagus | ESCC | Diabetic cardiomyopathy | 146/4205 | 203/8465 | 5.81e-11 | 7.78e-10 | 3.99e-10 | 146 |
| hsa04714211 | Esophagus | ESCC | Thermogenesis | 163/4205 | 232/8465 | 9.22e-11 | 1.14e-09 | 5.86e-10 | 163 |
| hsa05170210 | Esophagus | ESCC | Human immunodeficiency virus 1 infection | 147/4205 | 212/8465 | 3.37e-09 | 3.53e-08 | 1.81e-08 | 147 |
| hsa0521020 | Esophagus | ESCC | Colorectal cancer | 69/4205 | 86/8465 | 4.06e-09 | 4.13e-08 | 2.11e-08 | 69 |
| hsa05167211 | Esophagus | ESCC | Kaposi sarcoma-associated herpesvirus infection | 136/4205 | 194/8465 | 4.28e-09 | 4.22e-08 | 2.16e-08 | 136 |
| hsa0521216 | Esophagus | ESCC | Pancreatic cancer | 62/4205 | 76/8465 | 7.37e-09 | 6.85e-08 | 3.51e-08 | 62 |
| hsa0516510 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
| hsa0414010 | Esophagus | ESCC | Autophagy - animal | 101/4205 | 141/8465 | 7.60e-08 | 6.21e-07 | 3.18e-07 | 101 |
| hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
| hsa05163210 | Esophagus | ESCC | Human cytomegalovirus infection | 148/4205 | 225/8465 | 5.73e-07 | 4.00e-06 | 2.05e-06 | 148 |
| hsa0521516 | Esophagus | ESCC | Prostate cancer | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
| hsa0406629 | Esophagus | ESCC | HIF-1 signaling pathway | 75/4205 | 109/8465 | 3.66e-05 | 1.68e-04 | 8.60e-05 | 75 |
| hsa0522518 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
| hsa0501728 | Esophagus | ESCC | Spinocerebellar ataxia | 94/4205 | 143/8465 | 6.77e-05 | 2.90e-04 | 1.48e-04 | 94 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MTOR | SNV | Missense_Mutation | novel | c.7184A>G | p.Asn2395Ser | p.N2395S | P42345 | protein_coding | tolerated(1) | possibly_damaging(0.703) | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| MTOR | SNV | Missense_Mutation | c.7498N>T | p.Ile2500Phe | p.I2500F | P42345 | protein_coding | deleterious(0) | probably_damaging(0.926) | TCGA-A8-A06Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD | |
| MTOR | SNV | Missense_Mutation | rs769877976 | c.25G>A | p.Ala9Thr | p.A9T | P42345 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.835) | TCGA-A8-A08S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| MTOR | SNV | Missense_Mutation | novel | c.6287N>T | p.Asp2096Val | p.D2096V | P42345 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AN-A03Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MTOR | SNV | Missense_Mutation | novel | c.3142A>C | p.Ile1048Leu | p.I1048L | P42345 | protein_coding | tolerated(1) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MTOR | SNV | Missense_Mutation | novel | c.5276N>G | p.Leu1759Arg | p.L1759R | P42345 | protein_coding | tolerated(0.51) | probably_damaging(0.995) | TCGA-BH-A0AZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
| MTOR | SNV | Missense_Mutation | c.397N>G | p.Leu133Val | p.L133V | P42345 | protein_coding | deleterious(0) | possibly_damaging(0.563) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
| MTOR | SNV | Missense_Mutation | c.4835N>C | p.Arg1612Pro | p.R1612P | P42345 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD | |
| MTOR | SNV | Missense_Mutation | novel | c.3722N>G | p.Gln1241Arg | p.Q1241R | P42345 | protein_coding | tolerated(0.44) | benign(0.003) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MTOR | SNV | Missense_Mutation | c.7162N>C | p.Glu2388Gln | p.E2388Q | P42345 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | QUINACRINE | QUINACRINE | ||
| 2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | inhibitor | BEZ235 | DACTOLISIB | |
| 2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | TCMDC-125575 | CHEMBL587620 | ||
| 2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | PERPHENAZINE | PERPHENAZINE | ||
| 2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | PAZOPANIB | PAZOPANIB | 24625776 | |
| 2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | inhibitor | 249565693 | ||
| 2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | CAFFEIC ACID PHENETHYL ESTER | CAFFEIC ACID PHENETHYL ESTER | ||
| 2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | AZD2014 | VISTUSERTIB | ||
| 2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | GDC-0980/RG7422 | |||
| 2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | EVEROLIMUS | EVEROLIMUS | 24625776,25295501 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |